{"id":849013,"date":"2025-05-08T08:12:04","date_gmt":"2025-05-08T12:12:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/"},"modified":"2025-05-08T08:12:04","modified_gmt":"2025-05-08T12:12:04","slug":"alzamend-neuro-announces-reverse-stock-split","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/","title":{"rendered":"Alzamend Neuro Announces Reverse Stock Split"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ATLANTA, May  08, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Tl0NPaF-2E3MVnD7J9e-HQ3QrvMyOb5NtA9xsKxpor7jaVWv4hQKy29pbIFI5pOn0G1LYBxquhLOH4EL1JwRi3dMFoUlUu3d99948e5BqTQ=\" rel=\"nofollow\" target=\"_blank\">Alzamend Neuro, Inc.<\/a> (Nasdaq: ALZN) (\u201c<strong>Alzamend<\/strong>\u201d or the \u201c<strong>Company<\/strong>\u201d), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer\u2019s disease (\u201c<strong>Alzheimer\u2019s<\/strong>\u201d), bipolar disorder (\u201c<strong>BD<\/strong>\u201d), major depressive disorder (\u201c<strong>MDD<\/strong>\u201d) and post-traumatic stress disorder (\u201c<strong>PTSD<\/strong>\u201d), today announced that Alzamend\u2019s board of directors approved a one-for-nine reverse stock split of Alzamend\u2019s common stock (\u201c<strong>Common Stock<\/strong>\u201d) that will be effective in the State of Delaware at 12:01 a.m. Eastern Time on May 12, 2025. Beginning with the opening of trading on May 12, 2025, the Company\u2019s Common Stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the Company\u2019s existing trading symbol \u201cALZN\u201d. The new CUSIP number for the Common Stock will be 02262M605. The reverse stock split is part of the Company\u2019s plan to maintain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits.<\/p>\n<p align=\"justify\">The reverse stock split affects all issued and outstanding shares of the Company\u2019s Common Stock, as well as the number of shares of Common Stock available for issuance under the Company\u2019s equity incentive plans. In addition, the reverse stock split reduces the number of shares of Common Stock issuable upon the exercise of stock options or warrants outstanding immediately prior to the reverse split. The par value of the Company\u2019s Common Stock will remain unchanged at $0.0001 per share after the reverse stock split. The reverse stock split affects all stockholders uniformly and will not alter any stockholder\u2019s percentage interest in the Company\u2019s equity, except to the extent that the reverse stock split results in some stockholders owning a fractional share. No fractional shares will be issued in connection with the reverse split. Stockholders who would otherwise be entitled to receive a fractional share will instead receive a cash payment. As of the date of this press release, Alzamend has 7,208,591 shares of Common Stock issued and outstanding, which it anticipates will result in approximately 800,954 shares of Common Stock after the reverse stock split is effective.<\/p>\n<p align=\"justify\">Computershare Trust Company, N.A. (\u201c<strong>Computershare<\/strong>\u201d), is acting as the exchange agent and transfer agent for the reverse stock split. Computershare will provide instructions to stockholders for receiving payment for any fractional shares.<\/p>\n<p align=\"justify\">\n        <strong>About Alzamend Neuro<\/strong>\n      <\/p>\n<p align=\"justify\">Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer\u2019s, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 &#8211; a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate and L-proline, and ALZN002 &#8211; a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient\u2019s immunological system to combat Alzheimer\u2019s by removing beta-amyloid from the brain. The latter is a second-generation active-immunity approach designed to mitigate the disadvantages of approved passive immunity marketed antibody products, particularly by reducing the required frequency and costs of dosing associated with antibody products. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as \u201cbelieves,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cprojects,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201copportunity,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cpotential,\u201d or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend\u2019s business and financial results are included in Alzamend\u2019s filings with the U.S. Securities and Exchange Commission. All filings are available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2gqYZ0fDXGUR84cldDK48PlHHveJOTUpQUGNH6AIXio_3zGkloYWj96isMRk7sd2pHooIBlYKlgQVnNJaIOObg==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a> and on Alzamend\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FxMOiH16Sqc7nq7tKxSOEg3WDJK19gllX99U8Akx9g4bjEegM7IyHuyOE2aptqUiUlYOatD_c9pcOl3sJjfpe2obUs0oCJB3tb1pvU6FFjc=\" rel=\"nofollow\" target=\"_blank\">www.Alzamend.com<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <u>Contacts:<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=f1OIDa6UmWLKGfwDEu_RgsrAtVRAlfUjMf1odekTmZLhw0VJjXs4kAKMqnKgNYlsbkiYGZUm3wL2-NaRvXFnAy-u47GfZChgZS2gWOzn3jY=\" rel=\"nofollow\" target=\"_blank\">Info@Alzamend.com<\/a> or call: 1-844-722-6333<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NzI1OSM2OTI5MDcwIzUwMDEzMzAzMQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGNkODYzMGQtOTZkOS00MDQxLWFmYjMtODRlZGQyMjg2ZTk3LTUwMDEzMzAzMS0yMDI1LTA1LTA4LWVu\/tiny\/Alzamend-Neuro-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) &#8212; Alzamend Neuro, Inc. (Nasdaq: ALZN) (\u201cAlzamend\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer\u2019s disease (\u201cAlzheimer\u2019s\u201d), bipolar disorder (\u201cBD\u201d), major depressive disorder (\u201cMDD\u201d) and post-traumatic stress disorder (\u201cPTSD\u201d), today announced that Alzamend\u2019s board of directors approved a one-for-nine reverse stock split of Alzamend\u2019s common stock (\u201cCommon Stock\u201d) that will be effective in the State of Delaware at 12:01 a.m. Eastern Time on May 12, 2025. Beginning with the opening of trading on May 12, 2025, the Company\u2019s Common Stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the Company\u2019s existing trading symbol \u201cALZN\u201d. The new CUSIP number for the Common &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alzamend Neuro Announces Reverse Stock Split&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-849013","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alzamend Neuro Announces Reverse Stock Split - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alzamend Neuro Announces Reverse Stock Split - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) &#8212; Alzamend Neuro, Inc. (Nasdaq: ALZN) (\u201cAlzamend\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer\u2019s disease (\u201cAlzheimer\u2019s\u201d), bipolar disorder (\u201cBD\u201d), major depressive disorder (\u201cMDD\u201d) and post-traumatic stress disorder (\u201cPTSD\u201d), today announced that Alzamend\u2019s board of directors approved a one-for-nine reverse stock split of Alzamend\u2019s common stock (\u201cCommon Stock\u201d) that will be effective in the State of Delaware at 12:01 a.m. Eastern Time on May 12, 2025. Beginning with the opening of trading on May 12, 2025, the Company\u2019s Common Stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the Company\u2019s existing trading symbol \u201cALZN\u201d. The new CUSIP number for the Common &hellip; Continue reading &quot;Alzamend Neuro Announces Reverse Stock Split&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-08T12:12:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NzI1OSM2OTI5MDcwIzUwMDEzMzAzMQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-announces-reverse-stock-split\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-announces-reverse-stock-split\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alzamend Neuro Announces Reverse Stock Split\",\"datePublished\":\"2025-05-08T12:12:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-announces-reverse-stock-split\\\/\"},\"wordCount\":751,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-announces-reverse-stock-split\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NzI1OSM2OTI5MDcwIzUwMDEzMzAzMQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-announces-reverse-stock-split\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-announces-reverse-stock-split\\\/\",\"name\":\"Alzamend Neuro Announces Reverse Stock Split - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-announces-reverse-stock-split\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-announces-reverse-stock-split\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NzI1OSM2OTI5MDcwIzUwMDEzMzAzMQ==\",\"datePublished\":\"2025-05-08T12:12:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-announces-reverse-stock-split\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-announces-reverse-stock-split\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-announces-reverse-stock-split\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NzI1OSM2OTI5MDcwIzUwMDEzMzAzMQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NzI1OSM2OTI5MDcwIzUwMDEzMzAzMQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-announces-reverse-stock-split\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alzamend Neuro Announces Reverse Stock Split\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alzamend Neuro Announces Reverse Stock Split - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/","og_locale":"en_US","og_type":"article","og_title":"Alzamend Neuro Announces Reverse Stock Split - Market Newsdesk","og_description":"ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) &#8212; Alzamend Neuro, Inc. (Nasdaq: ALZN) (\u201cAlzamend\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer\u2019s disease (\u201cAlzheimer\u2019s\u201d), bipolar disorder (\u201cBD\u201d), major depressive disorder (\u201cMDD\u201d) and post-traumatic stress disorder (\u201cPTSD\u201d), today announced that Alzamend\u2019s board of directors approved a one-for-nine reverse stock split of Alzamend\u2019s common stock (\u201cCommon Stock\u201d) that will be effective in the State of Delaware at 12:01 a.m. Eastern Time on May 12, 2025. Beginning with the opening of trading on May 12, 2025, the Company\u2019s Common Stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the Company\u2019s existing trading symbol \u201cALZN\u201d. The new CUSIP number for the Common &hellip; Continue reading \"Alzamend Neuro Announces Reverse Stock Split\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-08T12:12:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NzI1OSM2OTI5MDcwIzUwMDEzMzAzMQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alzamend Neuro Announces Reverse Stock Split","datePublished":"2025-05-08T12:12:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/"},"wordCount":751,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NzI1OSM2OTI5MDcwIzUwMDEzMzAzMQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/","name":"Alzamend Neuro Announces Reverse Stock Split - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NzI1OSM2OTI5MDcwIzUwMDEzMzAzMQ==","datePublished":"2025-05-08T12:12:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NzI1OSM2OTI5MDcwIzUwMDEzMzAzMQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NzI1OSM2OTI5MDcwIzUwMDEzMzAzMQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alzamend Neuro Announces Reverse Stock Split"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/849013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=849013"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/849013\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=849013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=849013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=849013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}